Insmed (INSM) Q3 2026 earnings review
Insmed lung drug sales climb, while research costs jump
Insmed, a drug maker focused on rare and chronic lung diseases, expanded sales rapidly as its newest pill scaled up. Total revenue rose 23% from the second quarter to $524 million, led by Brinsupri, while quarterly cash burn shrank to $14 million. Chief executive Will Lewis raised the bottom of the full-year sales outlook for both commercial drugs, but by our math the plan points to Brinsupri quarterly growth slowing to 14% in the fourth quarter.
| Total revenue | $524.4M +23.3% from last quarter |
|---|---|
| Brinsupri revenue | $400.1M +29.4% from last quarter |
| Operating loss, excluding milestone adjustments | $81.8M $101.3M loss last quarter (by our math) |
| Full-year Brinsupri revenue outlook | Raised floor $100M middle of the range: $1.375B |
⚖️ Verdict: 🟢 Bullish
The story got better because rising Brinsupri sales cut the underlying operating loss and brought 2027 cash self-sufficiency within reach, while Japan opened as a new market and US regulators granted Priority Review to expand Arikayce. One caution: the third-quarter release and presentation did not report Brinsupri new patient starts or prescriber counts, and research spending jumped by $60 million from the prior quarter as four late-stage lung trials ramped up.
The question now is whether the fourth-quarter outlook reflects management caution or early patients stopping their Brinsupri prescriptions. If patients stay on the drug, fourth-quarter sales will beat the $1.4 billion annual ceiling; if refills drop off, sequential growth will slow sharply. Fourth-quarter results and any patient retention numbers from the call will tell.
🐂 Bull Case
Brinsupri Crosses $400 Million and Enters Japan
Brinsupri, Insmed's daily pill for a chronic lung condition called non-cystic fibrosis bronchiectasis, now brings in more than three-quarters of company sales. The drug maker wants it to lead revenue growth in the US and abroad. In the third quarter, Brinsupri revenue rose 29.4% from the second quarter to $400.1 million, and the biotech group launched the medicine in Japan in October after winning approval in August.
This matters because the drug reached a $1.6 billion yearly sales pace in its fourth full quarter on the market. Management also lifted the bottom of its 2026 Brinsupri sales plan by $100 million, to $1.35 billion. Furthermore, the Japanese launch opens a market where about 150,000 patients have a diagnosis and no other approved drug exists.
What to watch: fourth-quarter Brinsupri sales in the US and initial ordering in Japan when full-year results arrive in February. A total above $483 million would beat the top of the raised annual plan.
Higher Revenue Cut Quarterly Cash Burn to $14 Million
Finance chief Sara Bonstein has promised that the drug maker will generate positive cash flow in 2027 without selling more shares. On the surface, the reported operating loss widened from $1.5 million in the second quarter to $89.4 million in the third. However, a $99.8 million non-cash accounting gain on future milestone liabilities flattered the second-quarter figure.
Excluding those liability adjustments, the operating loss narrowed from $101.3 million in the second quarter to $81.8 million in the third, by our math. "Cash burn was lower than recent quarters, driven by higher revenue generation and appropriate financial discipline," Bonstein noted in the presentation. Total cash and marketable securities dipped by $13.7 million during the quarter to $1.15 billion, showing that rising product revenue is nearly covering current spending.
What to watch: ending cash and marketable securities in the fourth-quarter report. Holding the cash balance near $1.05 billion after paying $50 million in milestone fees to AstraZeneca would keep the 2027 cash goal on track.
Brinsupri Mix Lifted Product Gross Margin by 6 Points
Insmed sells two medicines with different production costs: Arikayce, an inhaled antibiotic delivered through a nebuliser, and Brinsupri, an oral tablet. In the third quarter, the cost of making products (excluding intangible asset charges) fell to 14.9% of revenue, down from 20.6% a year ago and 15.8% in the second quarter.
That 5.7 percentage point improvement from a year ago happened because Brinsupri is cheaper to manufacture than Arikayce and now makes up 76.3% of total sales. In addition, the biopharma company is still selling Brinsupri pills whose manufacturing costs were expensed as research before regulators approved the drug. That high gross margin gives management more cash to fund late-stage clinical trials.
What to watch: cost of product revenues as a share of sales in the quarterly filing. A jump toward 19% would signal that the pre-approval inventory has run out and normal manufacturing costs now apply.
Priority Review Sets Up Arikayce Expansion Next Year
Right now, US doctors can only prescribe Arikayce to lung infection patients who fail six months of standard treatment. Insmed wants to sell the drug to all patients with Mycobacterium avium complex (MAC) lung infection, which would expand the target market in the US and Japan beyond 200,000 people. In September, US regulators accepted the company's application for Priority Review and set a decision date of January 28, 2027.
Meanwhile, the clinical pipeline moved forward across multiple diseases. In September, the New Jersey company began dosing healthy volunteers in a Phase 1 trial of INS1033, a follow-on pill in the same drug class as Brinsupri aimed at rheumatoid arthritis. It also opened the third of four planned Phase 3 trials for TPIP, an inhaled powder for severe lung diseases, and noted "First data from gene therapy programs expected in 2027".
What to watch: the FDA decision on Arikayce by January 28, 2027, and the Japanese filing in the fourth quarter. Approval would allow a commercial launch for newly diagnosed patients in the first half of 2027.
🐻 Bear Case
The New Outlook Points to Slower Fourth-Quarter Growth
"BRINSUPRI’s U.S. launch continues to exceed expectations and ARIKAYCE continues to grow while in its ninth year on the market," chief executive Will Lewis said. To reflect that demand, Insmed lifted the bottom of its full-year Brinsupri outlook by $100 million, to a range of $1.35 billion to $1.40 billion, while keeping the top of the range unchanged.
- Second-quarter Brinsupri growth from the first quarter: 48.7%
- Third-quarter Brinsupri growth from the second quarter: 29.4%
- Fourth-quarter Brinsupri growth implied by the full-year outlook: 8.2% to 20.7% (14.5% at the middle of the range, by our math)
Holding the top of the range at $1.40 billion after generating $917.1 million in the first nine months leaves $432.9 million to $482.9 million for the fourth quarter, by our math. That implies quarterly sequential additions drop from $90.9 million in the third quarter to $57.8 million at the middle of the fourth-quarter range, because either new patient starts slow down or earlier patients stop refilling prescriptions.
What to watch: whether management discloses third-quarter new patient starts and prescription refill rates on the conference call or in the quarterly filing. A drop below 7,000 quarterly new starts would confirm that demand is cooling.
Pipeline Trials Drove a $60 Million Jump in Research Spend
Insmed is running three large Phase 3 trials for TPIP—covering pulmonary arterial hypertension and two forms of lung scarring—and plans to start a fourth in the first half of 2027. In the third quarter, research and development spending rose to $270.0 million, up from $186.4 million a year ago and $210.0 million in the second quarter. Selling and administrative costs also reached $253.0 million, up 35.8% from a year ago.
Even though revenue rose fast enough to shrink research spending as a share of sales by 79.5 percentage points from a year ago (to 51.5%), the $59.9 million dollar jump from the second quarter shows the heavy cost of TPIP manufacturing, trial enrollment, and hiring. Moreover, management warned that fourth-quarter spending will rise again to build the Japanese sales team and pay $50 million in milestones to AstraZeneca.
What to watch: fourth-quarter research and administrative expenses when full-year results print. If quarterly operating costs climb much past $650 million, reaching positive cash flow in 2027 will require even faster Brinsupri sales growth.
Risks this quarter didn't answer
Several standing concerns around patient retention, long-term sales targets, and rival drugs got no new data in the release or presentation.
- Brinsupri patient starts, prescriber counts, and refill persistence: absent from the release and slides; the conference call or quarterly filing will show whether quarterly additions held at 7,000 and whether doctors wrote more repeat scripts.
- Unrisked peak sales targets: management reiterated peak targets of over $7 billion for Brinsupri and over $6 billion for TPIP without giving a target year; TPIP's Phase 3 readouts after 2028 will test that claim.
- Rival drugs and customer concentration: clinical progress from Boehringer Ingelheim's competing pill and United Therapeutics' dry powder inhaler, plus the reliance on four distributors in the quarterly filing, will test pricing and market share.
👓 Other Themes
US Arikayce Stalls While Pricing Policy Limits Europe
In the US, Arikayce revenue grew 2.0% from a year ago to $75.5 million, holding nearly still ahead of next year's FDA expansion decision. Overseas Arikayce sales carried the drug, rising 21.3% to $48.9 million. For Brinsupri, Insmed launched in Japan after securing a favorable price, but it still has not launched in Europe or the UK, where government pricing rules have kept rollouts on hold.
💲 Other KPIs
Accounts receivable—money owed by specialty pharmacies and distributors for drugs already shipped—rose 20.4% from the second quarter and 84.1% from the end of 2025, by our math. That climb tracked the 23.3% quarterly rise in product revenue, tying up $43.9 million of working capital in the third quarter.
The average share count rose 3.3% from a year ago and 0.7% from the second quarter, by our math. Share growth slowed sharply after the company lapped its June 2025 stock offering, and management plans no new stock sales before reaching positive cash flow in 2027.
🔮 Guidance
Raised. Insmed lifted the bottom of the range by $100 million, pushing the middle of the plan up $50 million to $1.375 billion. By our math, that leaves $457.9 million at the middle of the range for Q4, or 14.5% growth from Q3 (down from 29.4% in Q3). The company noted that "BRINSUPRI guidance does not contemplate meaningful revenue contribution from Japan in 2026".
Raised. Management lifted the bottom of the range by $10 million, putting the middle of the plan at $465 million, or 7.2% growth for the year by our math. That leaves $126.2 million at the middle of the range for Q4, up 5.9% from a year ago vs 8.8% in Q3. If the pattern holds from the last two years (+3.0% average beat), full-year sales would reach $479 million.
Unchanged. The biopharma group kept its full-year forecast for Brinsupri price rebates and distributor discounts at roughly 25% to 29% of gross sales, after lowering the top end from the low-30%s last quarter. Third-quarter discounts landed inside this range.
Unchanged. Management kept its full-year plan for Arikayce price concessions and rebates at roughly 20% to 25% of gross sales. Third-quarter discounts stayed inside the target band for a third straight quarter.
❓ Key Questions
How many new patients started Brinsupri in Q3?
The earnings release and slides did not include quarterly new patient starts or cumulative prescribers, which stood at 7,000 and 6,300 in the second quarter. Without those figures, investors cannot separate new patient demand from prescription refills.
What percentage of Brinsupri patients stay on therapy?
Brinsupri has now been on the US market for four full quarters, yet management still has not shared six-month or twelve-month patient continuation rates. If early patients stop taking the pills, revenue growth will slow toward the pace of new starts.
What happened to the sinusitis and skin trials?
Insmed previously planned to report Phase 2b Brinsupri data in chronic rhinosinusitis (BiRCh) and hidradenitis suppurativa (CEDAR) in the first half of 2026. Neither trial appears in the third-quarter pipeline update, leaving their status unclear.
When does the pre-approval Brinsupri inventory benefit end?
Product manufacturing costs dropped to 14.9% of sales in part because early Brinsupri batches were expensed to research before FDA approval. Management has not said when higher-cost commercial inventory will flow through the income statement.